Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
Tesla Inc.’s troubles in China are growing and continue to eat at the company’s share of that country’s automotive market, according to new data. The China Passenger Car Association on Monday said ...
Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...
The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...
The category was the lone bright spot in the gaming retailer’s top-line results, as hardware and software both declined. GameStop’s latest earnings results come after second quarter wins in September, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback